Soham D. Puvvada

5.5k total citations · 2 hit papers
59 papers, 2.6k citations indexed

About

Soham D. Puvvada is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Soham D. Puvvada has authored 59 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 29 papers in Pathology and Forensic Medicine and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Soham D. Puvvada's work include Lymphoma Diagnosis and Treatment (29 papers), HER2/EGFR in Cancer Research (17 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Soham D. Puvvada is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), HER2/EGFR in Cancer Research (17 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Soham D. Puvvada collaborates with scholars based in United States, Spain and United Kingdom. Soham D. Puvvada's co-authors include Brad S. Kahl, Shekman Wong, John M. Pagel, Andrew W. Roberts, Martin Dunbar, Matthew S. Davids, Lori A. Gressick, Thomas J. Kipps, Ming Zhu and John F. Seymour and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Soham D. Puvvada

56 papers receiving 2.6k citations

Hit Papers

Targeting BCL2 with Venetoclax in Relapsed Chronic Lympho... 2015 2026 2018 2022 2015 2023 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    2015 1.3k citations Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine profile →
  2. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
    2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. profile →

Peers

Soham D. Puvvada
Thomas E. Boyd United States
Piers Blombery Australia
Alejandro Martı́n Spain
Stephen Opat Australia
Catherine Spier United States
Leslie A. Andritsos United States
Stephen E. Spurgeon United States
Andrew R. Pettitt United Kingdom
Enrico Tiacci Italy
Preetesh Jain United States
Thomas E. Boyd United States
Soham D. Puvvada
Citations per year, relative to Soham D. Puvvada Soham D. Puvvada (= 1×) peers Thomas E. Boyd

Countries citing papers authored by Soham D. Puvvada

Since Specialization
Citations

This map shows the geographic impact of Soham D. Puvvada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soham D. Puvvada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soham D. Puvvada more than expected).

Fields of papers citing papers by Soham D. Puvvada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soham D. Puvvada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soham D. Puvvada. The network helps show where Soham D. Puvvada may publish in the future.

Co-authorship network of co-authors of Soham D. Puvvada

This figure shows the co-authorship network connecting the top 25 collaborators of Soham D. Puvvada. A scholar is included among the top collaborators of Soham D. Puvvada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soham D. Puvvada. Soham D. Puvvada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, J-Y., Funda Meric‐Bernstam, Ana Oaknin, et al.. (2025). 145P Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. Annals of Oncology. 36. S251–S252. 1 indexed citations
2.
Oaknin, Ana, Jung‐Yun Lee, Vicky Makker, et al.. (2025). Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy. 42(5). 2015–2018. 2 indexed citations
3.
Oaknin, Ana, Jung‐Yun Lee, Vicky Makker, et al.. (2024). Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy. 41(11). 4125–4139. 9 indexed citations
4.
5.
6.
Meric‐Bernstam, Funda, Vicky Makker, Ana Oaknin, et al.. (2023). LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. Annals of Oncology. 34. S1273–S1274. 3 indexed citations
7.
8.
Amin, Amit Dipak, Lingxiao Li, Delphine Rolland, et al.. (2019). The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. Oncogene. 39(10). 2103–2117. 6 indexed citations
9.
10.
Amin, Amit Dipak, et al.. (2017). Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?. Molecular Case Studies. 3(3). a001719–a001719. 16 indexed citations
11.
Puvvada, Soham D., José Guillen-Rodriguez, Abhijeet Kumar, et al.. (2017). Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 18(1). 58–64. 6 indexed citations
12.
13.
Yun, Seongseok, Nicole D. Vincelette, Ivo Abraham, Soham D. Puvvada, & Faiz Anwer. (2016). Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. Acta Haematologica. 136(4). 244–255. 6 indexed citations
14.
McBride, Ali, Seongseok Yun, Irbaz Bin Riaz, et al.. (2016). Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. Critical Reviews in Oncology/Hematology. 109. 42–50. 54 indexed citations
15.
Kumar, Abhijeet, Srinath Sundararajan, Soham D. Puvvada, & Daniel O. Persky. (2016). Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?. Current Treatment Options in Oncology. 17(9). 45–45. 1 indexed citations
16.
Amin, Amit Dipak, Winnie S. Liang, Lori Cuyugan, et al.. (2015). Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors. Cancer Research. 75(14). 2916–2927. 28 indexed citations
17.
Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322. 1337 indexed citations breakdown →
18.
Gerecitano, John F., Andrew W. Roberts, John F. Seymour, et al.. (2015). A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. Blood. 126(23). 254–254. 60 indexed citations
19.
Puvvada, Soham D., Samantha Kendrick, & Lisa M. Rimsza. (2013). Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genetics. 206(7-8). 257–265. 17 indexed citations
20.
Schatz, Jonathan H., Elisa Oricchio, Soham D. Puvvada, & Hans‐Guido Wendel. (2013). Progress against follicular lymphoma. Current Opinion in Hematology. 20(4). 320–326. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas E. Boyd Breakdown of academic impact, for papers by Piers Blombery Breakdown of academic impact, for papers by Alejandro Martı́n Breakdown of academic impact, for papers by Stephen Opat Breakdown of academic impact, for papers by Catherine Spier Breakdown of academic impact, for papers by Leslie A. Andritsos Breakdown of academic impact, for papers by Stephen E. Spurgeon Breakdown of academic impact, for papers by Andrew R. Pettitt Breakdown of academic impact, for papers by Enrico Tiacci Breakdown of academic impact, for papers by Preetesh Jain
Rankless by CCL
2026